Modulating the nitric oxide - Cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension

International Journal of Clinical Practice

Volumn 64, Issue SUPPL. 168, 2010, Pages 15-22

  Lindman, B R ^a   Chakinala, M M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CELIPROLOL; CICLETANINE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; NEBIVOLOL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PERINDOPRIL; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; REACTIVE OXYGEN METABOLITE; RIOCIGUAT; SILDENAFIL; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

AORTA VALVE STENOSIS; CARDIOMYOPATHY; CLINICAL PRACTICE; CLINICAL TRIAL; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; EXERCISE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HUMAN; LUNG ARTERY PRESSURE; LUNG CONGESTION; LUNG VASCULAR RESISTANCE; MYOCARDIAL DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; SYSTOLIC HEART FAILURE; TACHYCARDIA; VALVULAR HEART DISEASE;

EID: 78649273251     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02524.x     Document Type: Review

References (68)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 1 (Suppl.): S43 - 54.
2. Gabbay E, et al. Am J Respir Crit Care Med 2007; 175: A713.
3. Zile MR, Baicu CF, Gaasch WH,. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953 - 9.
4. Zile MR, Brutsaert DL,. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387 - 93.
5. Aurigemma GP, Gaasch WH,. Clinical practice. Diastolic heart failure. N Engl J Med 2004; 351: 1097 - 105.
6. Kovacs G, Berghold A, Scheidl S, Olschewski H,. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888 - 94.
7. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004; 43: 1432 - 8.
8. Delgado JF, Conde E, Sanchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005; 7: 1011 - 6.
9. Fiack CA, Farber HW,. Pulmonary hypertension associated with left ventricular diastolic dysfunction. J Heart Lung Transplant 2010; 29: 230 - 1.
10. Faggiano P, Antonini-Canterin F, Ribichini F, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 2000; 85: 204 - 8.
11. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251 - 9.
12. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260 - 9.
13. Miyagishima K, Hiramitsu S, Kimura H, et al. Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction. Circ J. 2009; 73: 92 - 9.
14. Enriquez-Sarano M, Rossi A, Seward JB, et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997; 29: 153 - 9.
15. Aragam JR, Folland ED, Lapsley D, et al. Cause and impact of pulmonary hypertension in isolated aortic stenosis on operative mortality for aortic valve replacement in men. Am J Cardiol 1992; 69: 1365 - 7.
16. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53: 1119 - 26.
17. Kapoor N, Varadarajan P, Pai RG,. Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis. Eur J Echocardiogr 2008; 9: 31 - 3.
18. Pai RG, Varadarajan P, Kapoor N, Bansal RC,. Aortic valve replacement improves survival in severe aortic stenosis associated with severe pulmonary hypertension. Ann Thorac Surg 2007; 84: 80 - 5.
19. Malouf JF, Enriquez-Sarano M, Pellikka PA, et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 2002; 40: 789 - 95.
20. Little WC, Kitzman DW, Cheng CP,. Diastolic dysfunction as a cause of exercise intolerance. Heart Fail Rev 2000; 5: 301 - 6.
21. Grewal J, McCully RB, Kane GC, et al. Left ventricular function and exercise capacity. JAMA 2009; 301: 286 - 94.
22. Plehn G, Vormbrock J, Christ M, et al. Masked diastolic dysfunction caused by exercise testing in hypertensive heart failure patients with normal ejection fraction and normal or mildly increased LV mass. Acta Cardiol 2009; 64: 617 - 26.
23. Kitzman DW, Higginbotham MB, Cobb FR, et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991; 17: 1065 - 72.
24. Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010; 3: 477 - 85.
25. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391 - 479.
26. Routledge HC, Townend JN,. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity- J Hum Hypertens 2001; 15: 659 - 67.
27. Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004; 147: E19.
28. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin- converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004; 110: 1291 - 5.
29. Newby DE, Cowell SJ, Boon NA,. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both- Heart 2006; 92: 729 - 34.
30. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348: 1756 - 63.
31. Massion PB, Feron O, Dessy C, Balligand JL,. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003; 93: 388 - 98.
32. Belge C, Massion PB, Pelat M, Balligand JL,. Nitric oxide and the heart: update on new paradigms. Ann N Y Acad Sci 2005; 1047: 173 - 82.
33. Hofmann F, Feil R, Kleppisch T, Schlossmann J,. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006; 86: 1 - 23.
34. Lincoln TM, Dey N, Sellak H,. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001; 91: 1421 - 30.
35. Kass DA, Takimoto E, Nagayama T, Champion HC,. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 2007; 75: 303 - 14.
36. Piggott LA, Hassell KA, Berkova Z, et al. Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 2006; 128: 3 - 14.
37. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001; 104: 1286 - 91.
38. Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008; 118: 818 - 27.
39. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101: 812 - 8.
40. Rosenkranz AC, Dusting GJ, Ritchie RH,. Endothelial dysfunction limits the antihypertrophic action of bradykinin in rat cardiomyocytes. J Mol Cell Cardiol 2000; 32: 1119 - 26.
41. Rosenkranz AC, Hood SG, Woods RL, et al. Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. Hypertension 2002; 40: 498 - 503.
42. Ritchie RH, Schiebinger RJ, LaPointe MC, Marsh JD,. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 1998; 275 (4 Pt 2): H1370 - 4.
43. Fisher PW, Salloum F, Das A, et al. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005; 111: 1601 - 10.
44. Ichinose F, Bloch KD, Wu JC, et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 2004; 286: H1070 - 5.
45. Ruetten H, Dimmeler S, Gehring D, et al. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 2005; 66: 444 - 53.
46. Buys ES, Raher MJ, Blake SL, et al. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol 2007; 293: H620 - 7.
47. Takimoto E, Champion HC, Li M, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115: 1221 - 31.
48. Takimoto E, Kass DA,. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49: 241 - 8.
49. Silberman GA, Fan TH, Liu H, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 2010; 121: 519 - 28.
50. Wallis RM, Corbin JD, Francis SH, Ellis P,. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C - 12C.
51. Cremers B, Scheler M, Maack C, et al. Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. J Cardiovasc Pharmacol 2003; 41: 734 - 43.
52. Corbin J, Rannels S, Neal D, et al. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 2003; 19: 747 - 52.
53. Nagayama T, Hsu S, Zhang M, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 2009; 53: 207 - 15.
54. Kruger M, Kotter S, Grutzner A, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009; 104: 87 - 94.
55. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238 - 48.
56. Lu Z, Xu X, Hu X, et al. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 2010; 121: 1474 - 83.
57. Klinger JR,. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007; 28: 143 - 67, ix.
58. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105 - 13.
59. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89: 2035 - 40.
60. Melenovsky V, Al-Hiti H, Kazdova L, et al. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol 2009; 54: 595 - 600.
61. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005; 127: 1647 - 53.
62. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115: 59 - 66.
63. Guazzi M, Tumminello G, Di Marco F, et al. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44: 2339 - 48.
64. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555 - 62.
65. Robbins IM, Hemnes AR, Christman BW, et al. Phase I study to evaluate the efficacy of 6R-BH4 in subjects with pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: A3369.
66. Liao Y, Asakura M, Takashima S, et al. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 2004; 110: 692 - 9.
67. Kamp O, Metra M, Bugatti S, et al. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs 2009; 70: 41 - 56.
68. Munzel T, Gori T,. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009; 54: 1491 - 9.